Table 1.
Study, Year, (Country) | Study Design | Participants (No. of Women) | Sample Type | Exposure | Main Conclusions |
---|---|---|---|---|---|
Köse et al. (2014), Turkey [55] | Case–control study | 20: 10 with PCOS (mean age: 24.0 ± 5.5), 10 controls (mean age: 27.8 ± 6.9) | Peripheral whole blood sample | Se |
|
Guler et al. (2014), Turkey [56] | Prospective study | 86: 53 with PCOS (mean age: 25.4 ± 6.7), 33 controls (mean age: 28 ± 5.9) | Overnight fasting venous blood sample | Zn |
|
Jamilian et al. (2015), Iran [57] | Randomized, double-blind, placebo-controlled study | 48 with PCOS aged 18–40 | Fasting blood sample | Zn |
|
Jamilian et al. (2015), Iran [58] | Randomized, double-blind, placebo-controlled study | 60 with PCOS aged 18–40 | Fasting blood sample | Cr |
|
Razavi et al. (2016), Iran [59] | Randomized, double-blind, placebo-controlled study | 64 with PCOS aged 18–40 | Fasting blood sample | Se |
|
Razavi et al. (2016), Iran [60] | Randomized, double-blind, placebo-controlled study | 60 vitamin D deficient with PCOS aged 18–40 | Fasting blood sample | Ca |
|
Özer et al. (2016), Turkey [61] | Descriptive study | 124 aged 20–30: 71 with PCOS, 53 controls | Venous blood sample | Zn, Cu |
|
Ebrahimi et al. (2017), Iran [62] | Randomized double-blind, placebo-controlled tri-al | 60 with PCOS aged 18–40 | Fasting blood sample | Mg, Zn |
|
Jamilian et al. (2018), Iran [63] | Randomized, double-blind, placebo-controlled study | 40 infertile with PCOS, candidate for IVF, aged 18–40 | Fasting blood sample | Cr |
|
Shokrpour et al. (2019), Iran [64] | Randomized, double-blind, placebo-controlled study | 60 with PCOS aged 18–40 | Fasting blood sample | Mg |
|
Kanafchian et al. (2019), Iran [65] | Case–control study | 150 aged 20–40: 60 with PCOS, 90 controls | Fasting venous blood | Cu, Mg, Ca |
|
Kirmizi et al. (2020), Turkey [66] | Case–control study | 154: 84 with PCOS (aged 22–36), 70 controls (aged 21–39) | Blood sample | As, Cr, Cd, Sb, Hg, Pb, Cu, Zn |
|
Mousavi et al. (2021), Iran [67] | Randomized, double-blind, placebo-controlled study | 84 with PCOS aged 18–40 | Blood sample | Mg |
|
Abudawood (2021), Saudi Arabia [68] | Prospective study | 106 aged 19–35: 56 with PCOS, 50 controls | Blood serum | As, Cd, Pb, Hg |
|
Abudawood (2023), Saudi Arabia [69] | Case–control study | 106: 50 with PCOS (mean age: 30.41 ± 6.8), 56 controls (mean age: 29.16 ± 6.2) | Blood serum | Te, Tl, Sb, Os |
|
Abbreviations: As, arsenic; BMI, body mass index; Ca, calcium; Ca2+, neutrophil intracellular calcium concentration; CAT, catalase; Cd, cadmium; CPZ, capsazepine; Cr, chromium; Cu, copper; DHEA, dehydroepiandrosterone; DHEAS, dehydroepiandrosterone sulphate; FBG, fasting blood glucose; FSH, follicle-stimulating hormone; G/I ratio, glucose/insulin ratio; GPx, glutathione peroxidase; GSH, reduced glutathione; HbA1c, glycated haemoglobin; Hg, mercury; HOMA-IR, Homeostatic Model Assessment for Insulin Resistance; hs-CRP, high sensitivity C-reactive protein; IL-1, interleukin-1; IR, insulin resistance; LH, luteinizing hormone; LP, neutrophil lipid peroxidation; MDA, malondialdehyde; Mg, magnesium; NO, nitric oxide; Os, osmium; OSI, oxidative stress index (TOS/TAS ratio); 17-OH-P, 17-hydroxyprogesterone; Pb, lead; PCOS, polycystic ovary syndrome; PRL, prolactin; Sb, antimony; Se, selenium; SHBG, sex hormone-binding globulin; SOD, superoxide dismutase; QUICKI, quantitative insulin sensitivity check index; T, testosterone; TAC, total antioxidant capacity; TAS, serum total antioxidant status; Te, tellurium; TG, triacylglycerols; Tl, thallium; TNF-α, tumour necrosis factor alpha; TOS, total oxidant status; VLDL, very-low-density lipoprotein; Zn, zinc.